Up up up

Good luck trying to convince the general public
Could be over expectation but Affin started the ball rolling lol

Tomorrow banks will surge, expectations of special dividend lol

Top up at intervals
I added some at 0.52, maybe next 0.48

Tomorrow got chance again, DJIA very cheong

Eh? Windfall tax bukan go up meh per Natsuko.... Wah kena tipu!
Luckily I sot sot one, still keep tight tight lol

No show leh

Resistance is holding the line

Supermax engine warming up

Ok ok, I queue sell what I bought today

Pas is the past leh lol

Plantation sector, get set

Thanks for your tips Natsuko
I added some

Or less positive vs exchange rate

Take note likely gaming profits dropped a little as well, at least in NY
Just look at NY data I shared. Probably net net is neutral

I think it has stabilized, but still depends on US
This counter not for main lah

Next even would be Harta/Kossan announce results, in a few short weeks time

I think Kossan will stabilize at RM1.2x, below 1.30, let's see

Careplus another 7% lol
Losing money don't matter!

Those day traders all shift to Careplus to play contra lol

Not a buy/sell/hold call as always

Kossan no worries at current level, didn't surge up too much unlike some gloves which have no fundamental
Remember TP is actually higher at around RM1.30

If the market is steady, I think the next sector to look at would be plantation

Me and sharefisher in Kossan, didn't up that much but its a safer haven

https://www.gaming.ny.gov/gaming/index.php?ID=5

Checked the latest casino revenue for NY, net win generally down 10% vs peak in August

There is deep value la in certain glove counters, plunged below pre pandemic
Need to hold long term if you want stellar rise. Already profit, just hold for a while

Recently gloves buck the trend!

If drop from current level, quite dangerous lol

Consider 4.20

https://www.asgam.com/index.php/2022/10/15/scholars-say-macau-government-request-for-bidders-to-invest-more-out-of-step-with-reality/

Doesn't look good

Huh? Seems to be too wide a spread within 1 sector

Pas name is quite apt... Past

Rm5 is not easy if the market crashes. As usual, need to discount at least 20% from their TP

Haha, the buy signals actually auto walk-in the door

Nobody can catch the lowest

Just top up from time to time if you want in

Morgan TP RM7 by this year?
Means RM5 should be attainable. Let's see

I have a feeling shorties are in desperate times with gloves lol

The lower the better

Hi Mimi Siti, that was the worst youtube content I've ever seen, ever lol

Kossan showing weakness relative to the top 4
Maybe because it didn't drop too much earlier, or maybe shorties are coming back

Remember, they "plan" for 2023
Whether can be approved, is another question
Drug approvals are usually very slow process, which may need certain political ties or cost to make it "fast track"

Anyway, Maybank IB ascribed 1B USD value
https://www.theedgemarkets.com/article/genting-may-get-raise-shareholding-taurx-cheap-%E2%80%94-maybank-ib-research

Key highlight:
"We ascribe US$1 billion valuation to TauRx and raise our Genting SOP-based TP (target price) to RM5.35 from RM5.25. If TauRx is worth US$15 billion, Genting will be worth a much higher RM8.57 per share,"

I'm not sure how they derive the 1B value to only 10 sen share price (5.25 to 5.35)
And suddenly the TP jump to RM8.57 if Taurx is worth 15B (15x of 10 sen should be only RM1.50)

https://www.abdn.ac.uk/news/16439/

Key highlight:
TauRx plans to submit HMTM for regulatory approval in the UK, US and Canada in 2023, with other territories to follow

Overall market bearish, all above probably invalid lol

https://www.cnbc.com/2022/10/13/biogens-alzheimer-drug-could-be-more-competitive-than-peers-stifel-says-in-upgrade-to-buy.html

I don't subscribe so I can't read the article

I guess part of the reason for recent drop, is forward anticipation of additional finance cost on debt interest
The sins of high gearing

I didn't get news of any other country which has given approval for the drug. Do share if you're aware.
I do know some countries would rather depend on the result from US FDA as their own benchmark (shortcut?).
Also, US would be the biggest slice of the target market as well

Taurx is just a "possibility", what if approval failed? It is not a guarantee as of now

Glove sector getting crazy
Careplus is mad
Fast up fast down though

0.42% of net short selling